

CURRICULUM VITAE

George R. Aronoff, M.D., M.S., FACP, FASN
Vice President for Clinical Affairs
DaVita Kidney Care

Adjunct Professor of Medicine and Pharmacology
Division of Nephrology and Hypertension
University of Louisville School of Medicine

EDUCATION:

Undergraduate:

1968-1971 Indiana University
 Bloomington, Indiana
 (B.A., Chemistry, Distinction - 1972)

Graduate:

1971-1975 Indiana University School of Medicine
 Indianapolis, Indiana
 (M.D., Honors - 1975)

1979-1980 Graduate Student
 Department of Pharmacology
 Indiana University School of Medicine
 Indianapolis, Indiana
 (M.S., Pharmacology - 1984)

Postgraduate Professional Training:

1975-1976 Intern in Internal Medicine
 Indiana University School of Medicine
 Indianapolis, Indiana

1976-1977 Resident in Internal Medicine
 Indiana University School of Medicine
 Indianapolis, Indiana

1977-1978 Clinical Fellow
 Division of Nephrology
 Indiana University School of Medicine
 Indianapolis, Indiana

1978-1979 Chief Resident in Internal Medicine
 Wishard Memorial Hospital
 Indiana University School of Medicine
 Indianapolis, Indiana

1979-1980 Fellow in Clinical Pharmacology
Eli Lilly and Company
Indianapolis, Indiana

1979-1980 Research Fellow
Division of Nephrology
Indiana University School of Medicine
Indianapolis, Indiana

ACADEMIC & PROFESSIONAL EXPERIENCE:

Academic Appointments:

1977-1978 Instructor - Physical Diagnosis
Indiana University School of Medicine
Indianapolis, Indiana

1978-1979 Instructor in Medicine
Indiana University School of Medicine
Indianapolis, Indiana

1980-1983 Assistant Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana

1983-1987 Associate Professor of Medicine
Indiana University School of
Medicine
Indianapolis, Indiana

1985-1987 Associate Professor of Pharmacology
Indiana University School of Medicine
Indianapolis, Indiana

1983-1987 Adjunct Assistant Professor of Pharmacokinetics
Purdue University
School of Pharmacy and Pharmacal Sciences
West Lafayette, Indiana

1987-2014 Professor of Medicine
Division of Nephrology
University of Louisville School of Medicine
Louisville, Kentucky

1987-2014 Professor of Pharmacology
University of Louisville School of Medicine
Louisville, Kentucky

2014-Present Professor of Medicine-Gratis
Division of Nephrology and Hypertension
University of Louisville School of Medicine
Louisville, Kentucky

Hospital Appointments:

1980-1987 Indiana University Hospital
Wishard Memorial Hospital
Veterans Administration Medical Center
Indianapolis, Indiana

1987-2014 Alliant Medical Pavillion
Audubon Hospital
Baptist East Hospital
Jewish Hospital
Norton's Hospital
University of Louisville Hospital
Veterans Affairs Medical Center
Louisville, Kentucky

Clark County Hospital
Jeffersonville, Indiana

Other Professional Experience:

2013-2014 Assistant Chief Medical Officer
Renal Ventures Management, LLC
Lakewood, Colorado

2014-2017 Chief Medical Officer
Renal Ventures Management, LLC
Lakewood, Colorado

2017-Present Vice President for Clinical Affairs
DaVita Kidney Care
Denver, Colorado

BOARD CERTIFICATION:

- 1980 American Board of Internal Medicine
- 1982 American Board of Internal Medicine—Nephrology
- 1998 Special Certification in Hypertension—American Society of Hypertension

MEDICAL LICENSURE:

- 1975 Indiana 26183
Federal Licensing Examination
- 1987 Kentucky 25499

PROFESSIONAL and SCIENTIFIC SOCIETIES:

- American Association for the Advancement of Science
- American College of Physicians (Fellow 1985)
- American Federation for Medical Research
- American Society for Clinical Pharmacology and Therapeutics
(Member Medical Education Review Committee 1984-1986)
- American Society of Nephrology
(Chair, Informatics Committee 1997-2000)
- Central Society for Clinical Research
(Chair, Clinical Pharmacology Section 1994-1997)
- Inter-American Society for Chemotherapy
(Chairman, Division of Medicinal Chemistry and
Pharmacology - 1982-1987)
- Kentucky State Medical Association
- Jefferson County Medical Society (1987 – 2007)
- Greater Louisville Medical Society (2008 – present)
- Renal Physicians Association
(Board of Directors 1995-2002)
(Chair, Healthcare Payment Committee 1996-2000)
(Chair, Informatics Committee 1997-2000)
- National Kidney Foundation
(Region II President 1997-1999)
(National Medical Advisory Board Executive Committee 1997-1999)
- The Renal Network, Inc
(Member, Medical Review Board 1995 – 2007)
(Member, Board of Trustees 2001 – 2013)
(Chair, Data Subcommittee 1997 – 2001)

(Chair, Medical Review Board (2001 – 2007)
(President, Board of Trustees (2007 – 2013)
Network Strategies and Innovation
(President, Board of Trustees (2013 – 2016)
Qsource
(Member, Board of Directors (2016 -- Present)

Kidney Health Initiative
(Member, Board of Directors (2013 – 2014)
(Co-Chair, Pharmacokinetics in CRRT Work Group (2013 – 2014)

AWARDS AND NAMED LECTURESHIPS:

1969 Phi Eta Sigma - Honor Fraternity
1971 Phi Lambda Upsilon
Honor Chemical Society
1971 Phi Beta Kappa
1975 Alpha Omega Alpha
1982 Sigma Xi
1986 William N. Creasy Visiting Professor of Clinical
Pharmacology
Oregon Health Sciences University
Portland, Oregon
1995 Outstanding Lecturer - Department of Medicine,
University of Louisville
1995 Best Doctors in America - Midwest
2007 American College of Physicians – KY Chapter
University of Louisville, Teacher of Internal Medicine Award
2007-- 2016 Best Doctors in America
2008 Louisville Magazine - 2008 Innovative Doctor
2009 Louisville Magazine – Top Docs
2009 Nephrology Division—Didactic Teaching Award
2013 Louisville Magazine – Top Docs

Marquis Who's Who - Board Certified Medical Specialists
Marquis Who's Who - South and Southwest
Marquis Who's Who in America
Marquis Who's Who in Science and Engineering
Marquis Who's Who in Medicine and Healthcare

PATENTS

Gaweda; Adam E., Brier; Michael E.), Aronoff; George R., Jacobs; Alfred A. 2017. System and method for personalized dosing of pharmacologic agents. US Patent 9,852,267 filed September 28, 2012, and issued December 26, 2017.

ADMINISTRATIVE RESPONSIBILITIES:

1978-1979	Acting Director, Medical Intensive Care Unit Wishard Memorial Hospital Indianapolis, Indiana
1985-1987	Board of Directors University Medical Diagnostic Associates Indiana University School of Medicine and Hospitals Indianapolis, Indiana
1987-2009	Board of Directors (Secretary 1987-1991) University Medical Associates University of Louisville Louisville, Kentucky
1987-2009	Chief, Division of Nephrology Division of Nephrology Department of Medicine University of Louisville Louisville, Kentucky
2009-2014	Vice Chair for Clinical Affairs Department of Medicine University of Louisville Louisville, Kentucky
1987-1994	Fellowship Training Program Director Division of Nephrology University of Louisville Louisville, Kentucky
1987-1998	Medical Director University of Louisville Dialysis Unit Louisville, Kentucky

2004-2007	Medical Director Heart Transplantation Jewish Hospital Louisville, Kentucky
2013-2014	Assistant Chief Medical Officer Renal Ventures Management, LLC Lakewood, Colorado
2015-Present	Chief Medical Officer Renal Ventures Management, LLC Lakewood, Colorado
2017-Present	Vice President for Clinical Affairs DaVita Kidney Care Denver, Colorado

EDITORIAL BOARDS, ADVISORY COUNCILS AND COMMITTEES:

National Advisory Councils:

1980	Pharmacology Special Study Section Division of Research Grants National Institutes of Health Bethesda, Maryland
1995-2010	Editorial Board Hypertension Dialysis, and Clinical Nephrology (HDCN): Renal Diseases Electronic Journal
1984	Special Review Committee, NIDDKD National Institutes of Health Bethesda, Maryland
1987-1992	Medical Advisory Board SmithKline Beecham Laboratories Philadelphia, Pennsylvania
1988-1991	Safety Advisory Board Miles Pharmaceuticals West Haven, Connecticut

1989-1992	Merit Review Board For Alcoholism and Drug Dependence (Clinical Pharmacology) United States Department of Veterans Affairs Washington, D.C. Program Specialist
1990	Pharmacology Study Section (AHR-S1) Division of Research Grants National Institutes of Health Bethesda, Maryland
1992	National Kidney Foundation Spring Clinical Meetings Chicago, IL Advisory Board
1993-2013	Renal Physician's Association State and Regional Leadership Committee
2005-2008	Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) Gastroenterology and Urology Devices Advisory Panel

University Committee Service:

Indiana University Medical Center

1977-1978	Executive Council
1977-1978	Education Committee
1977-1978	Executive Council, Wishard Memorial Hospital
1981-1984	Research and Development Committee Veterans Administration Medical Center
1982-1984	Faculty Council
1982-1984	Athletic Affairs Committee
1981-1987	Advisory Committee Clinical Research Center

1983-1987	Biomedical Research Committee
1983-1987	Pharmacy & Therapeutics Committee
1983-1987	Student Promotions Committee
1983-1987	Lilly Clinic Institutional Review Committee

University of Louisville School of Medicine

1987-1992	Research and Development Committee Veterans Affairs Medical Center
1988-1990	Residency Evaluation Committee Department of Medicine
1989-1990	Pharmacy and Therapeutics Committee Humana Hospital-University of Louisville (Chairman - 1989-1990)
1991-1998	Renal Quality Assessment and Improvement Jewish Hospital
1992-1998	Investigational Drug Review Committee Jewish Hospital
1995-1996	Nutrition Committee Jewish Hospital
1995-1996	Pharmacology and Therapeutics Committee Jewish Hospital
2009 – 2010	ED/ICU Service Line Committee Jewish Hospital

Editorial Boards:

1981-1996	American Journal of Kidney Diseases
1981-1994	Antimicrobial Agents and Chemotherapy
1990-1996	Seminars in Dialysis
1981-1987	United States Pharmacopoeia Dispensing Information
1985-1988	Member, United States Pharmacopoeial Convention

1989-1992	Jefferson County Medical Society <u>Louisville Medicine</u> (Editor 1990, Editor-in-Chief 1991)
1996-2010	Hypertension, Dialysis and Clinical Nephrology (Clinical Pharmacology Section Editor)

DIRECTORATES AND SIMILAR APPOINTMENTS:

Public Service:

1979-1987	NeoFight - Parent Support Group Board of Directors (1979-1987)
1979-Present	National Kidney Foundation Board of Advisors--Spring Clinical Meeting (1991)
1979-1987	National Kidney Foundation of Indiana Board of Directors (1985-1987) Executive Committee (1985-1987)
1985-1987	Central Indiana Chapter, Kidney Foundation Board of Directors (1985-1987) Chairman, Fundraising (1985-1987)
1987-Present	National Kidney Foundation of Kentucky Board of Directors (1987-1992) Executive Committee (1988-1992) President, Medical and Scientific Advisory Board (1989-1992)
1998-2010	American Association of Kidney Patients Medical Advisory Board
1998	National Kidney Foundation National Medical Advisory Board, Executive Committee

TEACHING:

Courses taught:

Core Medicine Rotation for third year medical students

3—5 months per year

Emergency Lecture Series, Internal Medicine Residents

Developed lectures on Acid-Base and Electrolyte Emergencies (2 lectures each year)

Renal Didactic Series, Nephrology Fellows

Developed curriculum in hypertension, clinical pharmacology and business aspects of Nephrology practice (8 lectures each year)

Graduate Student Committees:

1983-1986	Michael E. Brier - Ph.D., 1986
1986-1988	Dorthea A. Griffiths - Ph.D.
1990-1993	Jennie Mangun - Ph.D.
1993-1995	Sharon Copler - M.S., 1995
1995-1997	David Hasselbacher – M.S., 1997
2006-2008	Adam Gaweda—M.S., 2008

GRANTS, CONTRACTS, INDUSTRIAL FUNDING AND FELLOWSHIPS:

1968-1970	Indiana University Alumni Association Indiana University, Bloomington, Indiana	
1978	Traveling Scholarship American Heart Association	
1979-1980	Training Grant - Hypertension PHS T32HL07181-03	\$ 10,000
	Eli Lilly & Company Pharmacokinetics of LY 127935	\$ 26,000
	Delbay Pharmaceuticals Pharmacokinetics of Mezlocillin in Patients with Liver Disease	\$ 26,000
	Eli Lilly & Company Nephrotoxicity of Vancomycin in Rats	\$ 7,000
	American Cyanamid Pharmacokinetics of Piperacillin in Patients with Renal Insufficiency	\$ 42,000
	Miles Pharmaceuticals Dose Dependent Pharmacokinetics of Mezlocillin in Patients with Renal Impairment	\$ 12,000
1981	Miles Pharmaceuticals Enteral Absorption of Mezlocillin in Rabbits	\$ 10,000
	Eli Lilly & Company Aminoglycoside Accumulation Kinetics in Rats	\$ 5,000
	Eli Lilly & Company Antibiotic Kinetics During Continuous Ambulatory Peritoneal Dialysis	\$ 24,000
1982	Eli Lilly & Company Moxalactam and Tobramycin Pharmacokinetics in Renal Impairment	\$ 43,000

	Eli Lilly & Company Cefamandole & Tobramycin Interactions	\$ 43,000
	Lederle Laboratories Effect of Topical Prostaglandin on the Development of Diabetic Microangiopathy in Rat Tail	\$ 5,000
	Eli Lilly & Company Pharmacokinetics of Fluoxetine in Renal Impairment	\$ 42,000
1983	Miles Pharmaceuticals Pharmacokinetics of Nitrendipine in Renal Impairment	\$ 41,000
	Eli Lilly & Company Pharmacokinetics of Ceftazidime in Renal Impairment	\$ 46,000
	Miles Pharmaceuticals Ciprofloxacin Kinetics	\$ 44,000
1984	Upjohn Company Solumedrol and Medrol Kinetics	\$ 10,000
	Hoffman LaRoche Cibenzoline Bioavailability and Kinetics in Renal Failure	\$ 57,615
	Eli Lilly & Company Pharmacokinetics of Penbutolol	\$ 37,691
	Eli Lilly & Company Pharmacokinetics of Nizatidine	\$ 67,105
	Eli Lilly & Company Pharmacokinetics of Pinacidil	\$ 64,436
1985	Wyeth ANF Renal Metabolism	\$ 12,000

1986	Eli Lilly & Company LY195115 Pharmacokinetics	\$ 72,100
	Beecham Laboratories Nabumetone Kinetics	\$ 61,000
	Eli Lilly & Company LY1460432 Pharmacokinetics	\$ 40,272
1987	Veterans Administration Merit Review Principle Investigator 1987-1989 ANF in Patients with COPD	\$184,000
	Beecham Laboratories Nabumetone Kinetics	\$ 60,000
	Hoffman-LaRoche Cilazapril Kinetics	\$ 42,000
1988	National Institutes of Health #R44DK36762-02 Artificial Kidney Membranes of Improved Biocompatibility. Subcontractor. (1988-1990)	\$ 63,017
1991	Department of Veterans Affairs Merit Review (1991-1996) Clinical Pharmacology of Drugs in Renal Impairment Principle Investigator	\$541,900
	Miles Pharmaceuticals Effects of aprotinin on renal function	\$108,000
1992	Upjohn, Inc. Pharmacokinetics and pharmacodynamics of glyburide in patients with end stage renal disease and type II diabetes mellitus	\$ 21,106
1996	Asahi Medical Company, Ltd. Reuse Studies of AM-SD Dialyzers	\$ 9,961
1997	Jewish Hospital Foundation, Inc. Medical Research Grant	\$ 47,354

	Predicting cyclosporine dosing using artificial neural networks	
	Alliant Community Trust Fund Determination of heparin dosing requirements using an artificial neural network	\$ 39,286
1998	National Kidney Foundation A demonstration project to assess the effect of Group work on health-related quality of life in ESRD	\$ 5,860
1999	Parke-Davis Pharmaceuticals Open Label, Phase 2 study to assess the interactions Of furosemide and oral YMO87 in CHF patients	\$142,620
2000	Indiana University – Co-Principal Investigator Readaptation to dialysis technology (subcontracted w/IU - NIH Grant) Dates: 4/1/00 – 3/31/02	\$ 10,005
2000	Luitpold Pharmaceuticals Comparison of oral iron with intravenous iron in patients with anemia of chronic renal failure not on dialysis Dates: 6/1/00 – 12/31/02	\$ 54,000
	Lilly Research Laboratories: Principal Investigator Pharmacokinetics and acute pharmacodynamics of LY333334 when administered alone and with Furosemide in stable chronic renal insufficiency Dates: 5/1/00 – 5/31/02	\$ 7,050
2001	Pharmacia Upjohn: Principal Investigator Zinecard for injection: evaluation of the effects of Renal dysfunction on the pharmacokinetics of Dexrazoxane Dates: 1/1/01 – 6.30/03	\$ 138,000
2001	American Heart Association: Co-principal Investigator Tyrosine phosphorylation of platelet plasma membrane Ca ²⁺ -ATPase in hypertension Dates: 1/1/01 – 12/30/03	\$214,500

2002	Luitpold Pharmaceuticals: Principal Investigator A study of the efficacy and safety of Venofer (iron sucrose injection) in anemic patients receiving peritoneal dialysis Dates: 6/02 – 7/03	\$18,000
2007	NxStage Medical, Inc: Principal Investigator FREEDOM: Following rehabilitation, economics and everyday-dialysis outcome measurements study. Dates: 04/07-04/11	\$68,040
2007	National Institutes of Health K25DK072085: Co-Mentor Intelligent Control Approach to Anemia Management Adam E. Gaweda, Principle Investigator Dates: 04/01/07—08/31/2012	\$716,877
2008	Merck & Co., Inc.: Principal Investigator A randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of Merck Staphylococcus aureus vaccine (V710) in adult patients with end-stage renal disease on chronic hemodialysis. Dates: 02/01/08-01/01/10	\$200,250
2012	National Institutes of Health R01DK093832: Co-Investigator Computational Approach to Personalized Anemia Management Adam E. Gaweda, Principle Investigator Dates: 09/01/12—07/31/16	\$581,158

CLINICAL SERVICE:

1987-2014 Hospital Attending

Attending physician on the Nephrology Service at Jewish, Norton, Audubon, Baptist East or Suburban Hospitals 3 to 5 months each year. Average inpatient census at Jewish 12 – 25 patients. Average census at Norton Hospital 8 – 16 patients. Responsible for primary patients and consults.

1987-2014 Outpatient clinics

Two ½ day clinics per week. Each clinic averages 1 — 14 patients on Tuesday and Thursday.

Dialysis shifts. One permanent shift of 31 patients. One permanent shift of 12 patients. Other shifts assigned on a monthly basis to fit the needs of physicians rounding at the various hospitals.

PUBLICATIONS: PEER REVIEWED ARTICLES:

Levitt EE, Aronoff GR, Morgan CD: A note on the possible limitations on the use of the Harvard Group Scale of Hypnotic Susceptibility, Form A. *Int J Clin Exp Hypnosis* 1974;22:234-238.

Levitt EE, Aronoff GR, Morgan CD, Overly TM, Parish MJ: Testing the coercive power of hypnosis: Committing objectional acts. *Int J Clin Exp Hypnosis* 1974;22:234-238.

Aronoff GR, Luft FC, Sloan RS, Maxwell DR: Mezlocillin pharmacokinetics in renal impairment. *Clin Pharmacol Ther* 1980;28:523- 528.

Aronoff GR, Sloan RS, Dinwiddie CB, Glant MD, Fineberg NS, Luft FC: Effects of vancomycin on renal function in rats. *Antimicrob Agents Chemother* 1981;19:306-308.

Aronoff GR, Sloan RS, Mong SA, Luft FC, Kleit SA: Moxalactam pharmacokinetics during hemodialysis. *Antimicrob Agents Chemother* 1981;19:575-577.

Lavelle KJ, Brier ME, Aronoff GR: Mezlocillin enteral absorption in rabbits. *Antimicrob Agents Chemother* 1981;20:418-419.

Luft FC, Aronoff GR, Evan AP, Connors BA: The effect of aminoglycosides on glomerular endothelium: a comparative study. *Res Commun Chem Pathol Pharmacol* 1981;34:89-95.

Aronoff GR: Mezlocillin elimination in patients with impaired renal function. *J Antimicrob Chemother* 1982;9:Suppl A:77-79.

Aronoff GR, Sloan RS, Luft FC: Pharmacokinetics of moxalactam in patients with normal and impaired renal function. *J Infect Dis* 1982;145:365-369.

Luft FC, Aronoff GR, Evan AP, Connors BA, Weinberger MH, Kleit SA: The renin-angiotensin system in aminoglycoside induced acute renal failure. *J Pharmacol Exp Ther* 1982;220:433-439.

Luft FC, Aronoff GR, Evan AP, Connors BA, Blase DK, Gattone VH: Effects of moxalactam and cefotaxime on rabbit renal tissue. *Antimicrob Agents Chemother* 1982;21:830-835.

Aronoff GR, Sloan RS, Stanish RS, Fineberg NS: Mezlocillin dose dependent elimination kinetics in renal impairment. *Eur J Clin Pharmacol* 1982;21:505-510.

Aronoff GR, Ozawa T, DeSante KA, Nash JF, Ridolfo AS: Benoxaprofen pharmacokinetics in renal impairment. *Clin Pharmacol Ther* 1982;32:190-194.

Aronoff GR, Pottratz S, Brier ME, Walker NE, Fineberg NS, Glant MD, Luft FC: Aminoglycoside accumulation kinetics in rat renal parenchyma. *Antimicrob Agents Chemother* 1983;23:74-78.

Gattone VH, Evan AP, Mong SA, Connors BA, Aronoff GR, Luft FC: The morphology of the renal microvasculature in glycerol and gentamicin induced renal failure. *J Lab Clin Med* 1983;101:183-195.

Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Cefazolin and cephalixin kinetics in continuous ambulatory peritoneal dialysis. *Clin Pharmacol Ther* 1983;33:66-72.

Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Mezlocillin kinetics in hepatic insufficiency. *Clin Pharmacol Ther* 1983;33:73-76.

Aronoff GR, Sloan RS, Brier ME, Luft FC: The effect of piperacillin dose on kinetics in renal impairment. *Eur J Clin Pharmacol* 1983;24:543-547.

Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Tobramycin kinetics during continuous ambulatory peritoneal dialysis. *Clin Pharmacol Ther* 1983;34:110-116.

Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Vancomycin kinetics during continuous ambulatory peritoneal dialysis. *Clin Pharmacol Ther* 1983;34:631-637.

Aronoff GR, Brier ME, Nierste DM, Sloan RS: Interactions of moxalactam and tobramycin in normal volunteers and in patients with impaired renal function. *J Infect Dis* 1984;149:9-15.

Evan AP, Mong SA, Connors BA, Aronoff GR, Luft FC: The effect of alloxan induced diabetes on the kidney. *Anat Rec* 1984;208:33-47.

Evan AP, Mong sm, Gattone VH, Connors BA, Aronoff GR, Luft FC: The effect of streptozotocin and streptozotocin induced diabetes on the kidney. *Renal Physiol* 1984;7:78-89.

Luft FC, Visscher DW, Nierste DM, Blase DK, Walker NA, Aronoff GR: Ceftazidime nephrotoxicity in rat. *Antimicrob Agents Chemother* 1984;25(4):513-514.

Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RD, Lemberger L: Fluoxetine kinetics and protein binding in patients with normal and impaired renal function. *Clin Pharmacol Ther* 1984;36:138-144.

Aronoff GR, Kenner CH, Sloan RS, Pottratz ST: Multiple-dose ciprofloxacin kinetics in normal subjects. *Clin Pharmacol Ther* 1984;36:384-388.

Abel SR, Aronoff GR: Evaluation of a microcomputer program for predicting tobramycin serum concentrations. *Am J Hosp Pharm* 1984;41:2397-2399.

Aronoff GR: Pharmacokinetics of Nitrendipine in patients with renal failure: a comparison to subjects with normal renal function. *J Cardiovasc Pharmacol* 1984;6:543-545.

Luft FC, Aronoff GR, Walker NA, Sloan RS, Fineberg NS: Determining specific gravity of urine with reagent sticks. *Clin Chem* 1984;30:582-583.

Luft FC, Aronoff GR, Sloan RS, Fineberg NS, Miller JZ, Free AH: The efficacy of quantitative and qualitative chloride titrators in the estimation of human salt intake. *Klin Wochenschr* 1985;63:62-67.

Brier ME, Mayer PR, Brier RA, Visscher D, Luft FC, Aronoff GR: Relationship between rat renal accumulation of gentamicin, tobramycin, and netilmicin and their nephrotoxicities. *Antimicrob Agents Chemother* 1985;27:812-816.

Luft FC, Aronoff GR, Sloan RS, Fineberg NS, Weinberger MH: Calcium channel blockade with nitrendipine - Effects on sodium homeostasis, the renin-angiotensin system, and the sympathetic nervous system in humans. *Hypertension* 1985;7:438-442.

Kenner CH, Evan AP, Blomgren P, Aronoff GR, Luft FC: Effect of protein intake on renal function and structure in partially nephrectomized rats. *Kidney Int* 1985;27:739-750.
Aronoff GR, Sloan RS: Nitrendipine kinetics in normal and impaired renal function. *Clin Pharmacol Ther* 1985;38:212-218.

Aronoff GR, Maxwell DR, Batteiger BE, Fineberg NS: Hepatitis B virus vaccine--a randomized trial of a reduced dose regimen in hemodialysis patients. *Am J Kidney Dis* 1985;6:170-172.

Brashear RL, Aronoff GR, Brier RA: Activated charcoal in theophylline intoxication. *J Lab Clin Med* 1985;106:242-245.

Lui A, Lumeng L, Aronoff GR, Li TK: Relationship between body store of vitamin B6 and plasma pyridoxal-P clearance: Metabolic balance studies in man. *J Lab Clin Med* 1985;106:491-497.

Aronoff GR, Wong D, Sloan RS, Walker NE, Luft FC: Solid-phase reagent strip for plasma and urine creatinine measurements. *Lab Med* 1986;17:41-43.

Luft FC, Lang RE, Aronoff GR, Ruskoaho H, Toth M, Ganten D, Sterzel RB, Unger T: Atriopeptin III kinetics and pharmacodynamics in normal and anephric rats. *J Pharmacol Exp Ther* 1986;236:416-418.

Luft FC, Aronoff GR, Sloan RS, Fineberg NS, Weinberger MH: Short term augmented calcium has no effect on sodium homeostasis. *Clin Pharmacol Ther* 1986;39:414-419.

Luft FC, Aronoff GR, Sloan RS, Fineberg NS: Intra- and inter- individual variability in sodium intake in normal subjects and patients with renal insufficiency. *Am J Kidney Dis* 1986;7:375-380.

Aronoff GR, Wolen RL, Oberymer BD, Black HR: The pharmacokinetics and protein binding of cefamandole and its methyl-tetrazole-thiol side-chain in subjects with normal and impaired renal function. *J Infect Dis* 1986;133:1069-1074.

Sullivan TY, DeWeese EL, Yu PL, Aronoff GR: Ventilatory response during CO₂ inhalation after airway anesthesia with lidocaine. *J Appl Physiol* 1986;61:2230-2237.

Brier ME, Aronoff GR, Mayer PR: The effect of acute renal failure on insulin disposition in the isolated perfused rat kidney. *Am J Physiol* 1987;253:F884-F888.

Brier ME, Brier RA, Luft FC, Aronoff GR: Kinetics and pharmacodynamics of atrial natriuretic peptide and lithium clearance in the isolated perfused rat kidney. *J Pharmacol Exp Ther* 1987;243:868-873.

Sullivan TY, Deweese EL, Yu PL, Aronoff GR: Lung mechanics and neuromuscular output during CO₂ inhalation after airway anesthesia. *J Appl Physiol* 1987;63:2542-2548.

Callaghan JT, Bergstrom RF, Rubin A, Chernick S, Crabtree R, Knadler MP, Obermeyer B, Offen WW, Schneck DW, Aronoff G: A pharmacokinetic profile of nizatidine in man. *Scand J Gastroenterol* 1987;136:9-17.

Aronoff GR, Bergstrom RF, Bopp RJ, Sloan RS, Callaghan JT: Nizatidine disposition in subjects with normal and impaired renal function. *Clin Pharmacol Ther* 1988;43:688-695.

Luft FC, Aronoff GR, Fineberg NS, Weinberger MH: Facilitation of natriuresis with nifedipine in normal humans. *J Cardiovasc Pharmacol* 1988;12:S120-122.

Luft FC, Aronoff GR, Fineberg NS, Weinberger MH: Effects of oral calcium, potassium and nifedipine on natriuresis in normal humans. *American J Hypertension* 1989;2:14-19.

Carlone S, Palange P, Salatto MP, Serra P, Weinberger MH, Aronoff GR, Sullivan TY, Mannix ET, Manfredi F, Cockerill EM, Farber MO: Atrial natriuretic peptide, renin and aldosterone in obstructive lung disease and heart failure. *Am J Med Sci* 1989;298(4):243-248.

Aronoff GR, Sloan RS, Brier RA: Ceftazidime and tobramycin interactions in patients with normal and impaired renal function. *Antimicrobial Agents & Chemother* 1990;34(6):1139-1142.

Fried T, Aronoff GR, Benabe JE, Brunner HR, DeBona GF, Fleischam T, Lam M, Lawton WJ, Luft FC, Martinez-Maldonado M, McCullough A, Petrillo A: The renal and hemodynamic effects of atrial natriuretic peptide in patients with cirrhosis. *Amer J Med Sci* 1990;299(1):2-9.

Mannix ET, Dowdeswell I, Carlone S, Palange P, Aronoff GR, Farber MO: The effect of oxygen on sodium excretion in hypoxemic patients with chronic obstructive lung disease. *Chest* 1990;97:840-44.

Carlone S, Palange P, Mannix ET, Farber MO, Aronoff GR, Brier M, Serra P, Manfredi F: Effect of positive and negative pressure breathing on sodium and water excretion. *J Lab Clin Med* 1990;116:298-304.

Aronoff GR, Duff DR, Sloan RS, Brier ME, Maurice B, Erickson B, Golper TA: The treatment of anemia with low-dose recombinant human erythropoietin. *Am J Nephrol* 1990;10(2):40-43.

Mannix ET, Palange P, Aronoff GR, Manfredi F, Farber MO: Atrial natriuretic peptide and the renin aldosterone axis during exercise in man. *Med Sci Sports Exerc* 1990;22(6):785-789.

Aronoff GR, Brier M, Mayer ML, Barbalas M, Aogaichi KB, Sloan R, Brazzell R, Masserella JW: Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. *J Clin Pharmacol* 1991;31:38-44.

Duff DR, Golper TA, Sloan RS, Brier ME, Aronoff GR: Low dose recombinant erythropoietin therapy in chronic hemodialysis patients. *Am J Kid Dis* 1991;18(1):60-64.

Mannix ET, Farber MO, Aronoff GR, Cockerill E, Ryan T, Sullivan TY, Carlone S, Palange P, Galassetti P, Serra P, Manfredi F: Regulation of atrial natriuretic peptide release in normal humans. *J Appl Physiol* 1991;71(4):1340-1345.

Mannix ET, Manfredi F, Palange P, Aronoff GR, Weinberger MH, Farber MO: The effect of oxygen with exercise on atrial natriuretic peptide in obstructive lung disease. *Chest* 1992;101:341-344.

Wedler B, Brier ME, Wiersbitzky M, Gruska S, Wolf E, Kalwellis R, Aronoff GR, Luft FC: Sodium kinetics in salt-sensitive and salt-resistant normotensive and hypertensive subjects. *J Hypertension* 1992;10:663-669.

Aronoff GR: Therapeutic implications associated with renal studies of nabumetone. *J Rheumatol* 1992;19 Suppl:25-31.

Brier ME, Bunke CM, Lathon PV, Aronoff GR: Erythropoietin-induced antinatriuresis induced by angiotensin II. *J Am Soc Nephrol* 1993;3(9):1583-90.

Sica DA, Midha M, Aronoff G, Bergen G: Atrial natriuretic factor in spinal cord injury. Arch Phys Med Rehabil 1993;Sep 74(9):969-72.

Dean WL, Pope JE, Brier ME, Aronoff GR: Platelet calcium transport in hypertension. Hypertension 1994;23(1):31-37.

Brier ME, Aronoff GR: Initial intraperitoneal therapy for CAPD peritonitis: The network 9 peritonitis study. Adv. Peritoneal Dialysis 1994; 10:141-143.

Brier ME, Zurada JM, Aronoff GR: Neural network predicted peak and trough gentamicin concentrations. Pharmaceutical Research 1995; 12:406-412.

Brier ME, Sloan RS, Aronoff GR: Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. Clinical Pharmacology & Therapeutics 1995; 57:622-627.

Brier ME, Lathon PV, Aronoff GR, Luft FC: Pharmacodynamics of atrial natriuretic peptide in isolated perfused dahl rat kidneys. Hypertens Res 1995; 18:219-225.

Brier ME, Aronoff GR: Application of artificial neural networks to clinical pharmacology. Int. J Clin Pharmacol 1996; 34:510-514.

Mannix ET, Farber MO, Aronoff GR, Brier ME, Weinberger MH, Palange P, Manfredi F: Hemodynamic renal and hormonal responses to lower body positive pressure in human subjects. J Lab Clin Med 1996; 128:585-593.

Brier ME, Bays H, Sloan R, Stalker DJ, Welshman I, Aronoff GR. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. American Journal of Kidney Diseases. 1997; 29(6):907-11.

Aronoff G: Informatics and end-stage renal disease. Advances in Renal Replacement 1998; 5:292-298.

Lee F, Kar PM, Aronoff GR: Treatment of cryptococcal arthritis with fluconazole monotherapy. Journal of the Kentucky Medical Association 1998; 96:449-450.

Aronoff G: Non-prescription drugs: what kidney patients should know. AAKP15:6-, 1999.

Blankenship KA, Dawson CB, Aronoff GR, Dean WL: Tyrosine phosphorylation of human platelet plasma membrane Ca(2+)-ATPase in hypertension. Hypertension 2000; 35:103-107.

Van Wyck DB, Bailie G, Aronoff G: Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease. Am. J. Kid. Diseases 2002; 39:426-432.

Frankenfield DL, Brier ME, Bedinger MR, Milam RA, Eggers PW, Cain JA, Aronoff GR, Frederick PR: Comparison of urea reduction ratio and hematocrit data reported in different data systems: results from the Centers for Medicare and Medicaid Services and the Renal Network, Inc. *Am. J. Kid. Diseases* 2003; 41:433-441.

Brier ME, Stalker DS, Aronoff GR, Batts DH, Ryan KK, O'Grady M, Hopkins N, Jungbluth GL: Pharmacokinetics of linezolid in subjects with renal dysfunction. *Antimicrobial Agents and Chemotherapy* 47(9):2775-80, 2003.

Van Wyck DB, Danielson BG, Aronoff GR: Making sense: a scientific approach to intravenous iron therapy. *J. Am. Soc. Neph.* 15(S2):S91-S92, 2004.

Aronoff G, Bennett Wm, Blumenthal S, Charytan C, Pennell JP, Reed J, Rothstein M, Strom J, Wolfe A, Van Wyck D, Yee J: Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. *Kid. Int.* 66:1193-1198, 2004.

Gaweda AE, Muezzinoglu MK, Aronoff GR, Jacobs AA, Zurada JM, Brier ME: Individualization of pharmacological anemia management using reinforcement learning. *Neural Networks* 18:826-834, 2005.

Gaweda AE, Muezzinoglu MK, Jacobs AA, Aronoff GR, Brier ME. Model Predictive Control with Reinforcement Learning for Drug Delivery in Renal Anemia Management, Proceedings 28th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, pp. 5177-5180, 2006.

Gaweda AE, Muezzinoglu MK, Aronoff GR, Jacobs AA, Zurada JM, Brier ME. Using Clinical Information in Goal-Oriented Learning: Incorporating Clinical Expertise into Computational Framework to Improve Outcomes for Anemia Management. *IEEE Engineering in Medicine and Biology* 26:27-36, 2007.

Gaweda AE. Jacobs AA. Aronoff GR. Brier ME. Model predictive control of erythropoietin administration in the anemia of ESRD. *American Journal of Kidney Diseases.* 51:71-79, 2008 Jan.

Gaweda AE. Goldsmith LJ. Brier ME. Aronoff GR. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. *CJASN* 5(4):576-81, 2010.

Brier ME. Gaweda AE. Dailey A. Aronoff GR. Jacobs AA. Randomized trial of model predictive control for improved anemia management. *CJASN* 5(5):814-20, 2010.

Brier ME, Gaylor SK, McGovren JP, Glue P, Fang A, Aronoff GR. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. *J Clin Pharmacol*. 2011 May;51(5):731-8.

Gaweda AE, Nathanson BH, Jacobs AA, Aronoff GR, Germain MJ, Brier ME. Determining optimum hemoglobin sampling for anemia management from every-treatment data. *Clin J Am Soc Nephrol*. 2010 Nov;5(11):1939-45.

Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2011 Dec;80(11)

Moustafa M, Aronoff GR, Chandran C, Hartzel JS, Smugar SS, Galphin CM, Mailloux LU, Brown E, Dinubile MJ, Kartsonis NA, Guris D. Phase IIa study of the immunogenicity and safety of the novel *Staphylococcus aureus* vaccine V710 in adults with end-stage renal disease receiving hemodialysis. *Clin Vaccine Immunol*. 2012 Sep;19(9):1509-16.

Dwyer A, Shelton P, Brier M, Aronoff G. A vascular access coordinator improves the prevalent fistula rate. *Semin Dial*. 2012 Mar-Apr;25(2):239-43.

Gaweda AE, Aronoff GR, Jacobs AA, Rai SN, Brier ME. Individualized anemia management reduces hemoglobin variability in hemodialysis patients. *J Am Soc Nephrol*. 2014 Jan;25(1):159-66.

Reddy N, Sukheswalla F, Aronoff GR. The first 120 days of crucial care: Strategies for managing incident dialysis patients. *Nephrol News Issues*. 2015 Jul;29(8):27-31.

Reddy N, Aronoff GR. Telehealth monitoring decreases missed treatments in new dialysis patients. *Nephrol News Issues*. 2016 Aug;30(8):35-36.

Gaweda AE, Jacobs AA, Aronoff GR, Brier ME. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience. *Clin Nephrol*. 2018 Oct;90(4):276-285

Brunelli SM, Cohen DE, Marlowe G, Liu D, Njord L, Van Wyck D, Aronoff G. Safety and efficacy of heparin during dialysis in the context of systemic anticoagulant and antiplatelet medications. *J Nephrol*. 2019 Jun;32(3):453-460. doi: 10.1007/s40620-018-00576-w. Epub 2019 Jan 2.

PUBLICATIONS: CLINICAL OBSERVATIONS, INVITED REVIEWS:

Aronoff GR, Hamburger RJ: Special uses of cimetidine. *Ann Intern Med* 1978;88:266-267.

Aronoff GR, Luft FA: Antimicrobial therapy in impaired renal function. *DialTranspl* 1979;8:14-17.

Aronoff GR, Friedman S, Doedens D, Lavelle KJ: Increased serum iodide concentrations from iodide absorption through wounds treated topically with povidone-iodine. *Am J Med Sci* 1980;279:173-178.

Aronoff GR, Szwed JJ, Nelson RL, Marcus EL, Kleit SA: Hypoxanthine- Arabinoside pharmacokinetics following administration of adenosine arabinoside to a patient with renal failure. *Antimicrob Agents Chemother* 1980;18:212-214.

Green FJ, Lavelle KJ, Aronoff GR, Vander Zanden J, Brier GL: Management of amikacin overdose. *Am J Kidney Dis* 1981;1:110-112.

Leff RD, Smith EJ, Aldo-Benson MA, Aronoff GR: Cryptococcal arthritis after renal transplantation. *South Med J* 1981;74:1290.

Luft FC, Lavelle KJ, Aronoff GR: Common nephrotoxic reactions from diagnostic and therapeutic agents. *J Ind State Med Assoc* 1982;75:255-257.

Lavelle KJ, Aronoff GR, Luft FC: The effect of non-steroidal anti- inflammatory agents on renal function. *J Ind State Med Assoc* 1982;75:334-336.

Aronoff GR, Luft FC, Lavelle KJ: Antimicrobial therapy in patients with impaired renal function. *J Ind State Med Assoc* 1982;75:392-394.

Luft FC, Aronoff GR, Evan AP, Connors BA, Weinberger MH, Kleit SA: The effect of captopril on gentamicin induced acute renal failure. Eliahou H (ed), John Libbery, London, *Exp ARF & Nephrotoxins*, 108- 111, 1982.

McCloskey RV, LeFrock JL, Smith BR, Aronoff GR: Microbiology, pharmacology, and clinical use of mezlocillin sodium. *Pharmacotherapy* 1982;2:300-312.

Luft FC, Aronoff GR, Lavelle KJ: Disturbances in the serum sodium concentration. J Ind State Med Assoc 1983;76:582-586.

Aronoff GR: Antimicrobial therapy in patients with impaired renal function. Am J Kidney Dis 1983;3:106-110.

Bunke CM, Aronoff GR, Luft FC: Pharmacokinetics of common antibiotics used in CAPD. Am J Kidney Dis 1983;3:114-117.

Lavelle KJ, Luft FC, Aronoff GR: Disorders of potassium balance. J Ind State Med Assoc 1983;76:684-687.

Aronoff GR, Lavelle KJ, Luft FC: A practical approach to acid base disorders. J Ind State Med Assoc 1983;76:764-766.

Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, Singer I. Drug prescribing in renal failure - dosing guidelines for adults. Am J Kidney Dis 1983;3:155-193.

Lemberger L, Bergstrom R, Aronoff G, Farid N, Wolen R: Specific serotonin uptake blockers: clinical pharmacology and antidepressant action. Clin Neuropharmacol 1984;7:324-325.

Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR: Fluoxetine clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985;46:14-19.

Aronoff GR: Achieving therapeutic balance in patients with renal disease. Contemporary Internal Med 1989;1:45-48.

Matzke GR, Schwenk MH, Keane WF: Antibiotics: Vancomycin. In: Aronoff GR (ed), Practical guidelines for drug therapy in dialysis. Seminars in Dialysis 1989;2:54-55.

Aronoff GR: Practical therapeutics in patients with renal impairment. Western J Med 1992;156:664.

Aronoff GR: Nonsteroidal anti-inflammatory drug related renal syndromes. J Kentucky Med Assoc 1992;90:336-339.

Harris EE, Sweat M, Katsanis WA, Aronoff GR: Case Report: acute focal bacterial pyelonephritis (lobar nephronia) -- presentation as a palpable abdominal mass. Am J Med Sci 1992;304:303-305.

Kar PM, Leehey D, Aronoff GR: Pseudo-pericardial friction rub. J Ky Med Assoc 1992;90:528.

Kar PM, Aronoff G, Schuette P: Bronchopulmonary disease: an association with ulcerative colitis and pyoderma gangrenosum. J Ky Med Assoc 1993;91(8):320-3.

Aronoff GR, Drugs and the kidney. *Curr Opin Nephrol Hypertens* 1993 Mar; 2(2):187-9.

Aronoff G, Brater DC, Schrier R, Bennett WM. Use of drugs in patients with renal insufficiency. Workshop Report. *Blood Purif* 1994; 12(1):14-9.

Aronoff, GR: A practical approach to drug prescribing for patients with impaired renal function. In: Hartmut H. Malluche, MD, (eds). *Mediguide to Nephrology* 1995; 1-8.

Aronoff GR, Coffin R, Stark S, Wish J: NephTrak and the Renal Network Data System (TRNDS). *Nephrology News and Issues*, 2001, 15:31-35.

Aronoff GR: Lowering the Risk of Heart Disease. *Renalife* 2001, 16:5-9.

Aronoff GR, Cain J, Carson B, Stark S, Wish J: Goal Setting and Network 9/10 Efforts to Improve Care. *Nephrology News and Issues*, 2001, 15:58-60.

Aronoff GR: Safety of intravenous iron in clinical practice: implications for anemia management protocols. *J. Am. Soc. Neph.* 15(S2):S99-S106, 2004.

Aronoff GR: Dose adjustment in renal impairment: response from drug prescribing in renal failure. *BMJ* 331:293-294, 2005.

Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. *J Am Soc Nephrol.* 2009 Mar;20(3):479-87.

Ward RA, Aronoff GR. Recognizing and reacting to product-related adverse events in hemodialysis. *Am J Kidney Dis.* 2010 Jan;55(1):11-4.

Panchabhai TS, Aronoff GR. Massive cystic liver in a patient with autosomal dominant polycystic kidney disease. *Southern Medical Journal.* 103(7):718-20, 2010.

Alfaro R, Vasavada N, Paueksakon P, Hernandez GT, Aronoff GR. Cocaine-induced acute interstitial nephritis: A case report and review of the literature. *J Nephropathol.* 2013 Jul;2(3):204-9.

Aronoff GR, Gaweda AE. Balancing ESA and iron therapy in a prospective payment environment. *Nephrol News Issues.* 2014 Feb;28(2):16-8.

Aronoff GR, Aronoff JR. Drug prescribing in kidney disease: can't we do better? *Am J Kidney Dis.* 2014 Mar;63(3):382-3.

Parker TF 3rd, Aronoff GR. The Medical Director in Integrated Clinical Care Models. *Clin J Am Soc Nephrol.* 2014 Oct 28.

Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leypoldt JK, Witcher JW, Zineh I, Archdeacon P, Roy-Chaudhury P, Goldstein SL. Pharmacokinetic Assessment in Patients Receiving Continuous RRT: Perspectives from the Kidney Health Initiative. Clin J Am Soc Nephrol. 2015 Jan 7;10(1):159-64.

Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant. 2015 Feb;30(2):187-196.

Parker TF 3rd, Aronoff GR. The medical director in integrated clinical care models. Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1282-6.

Aronoff GR. The effect of treatment time, dialysis frequency, and ultrafiltration rate on intradialytic hypotension. Semin Dial. 2017 Nov;30(6):489-491.

Wish JB, Aronoff GR, Bacon BR, Brugnara C, Eckardt K-U, Ganz T, Macdougall IC, Nunez J, Perahia AJ, Wood JC. Positive iron balance in chronic kidney disease: how much is too much and how to tell? Am J Nephrol 2018;47:72-83.

Brier ME, Gaweda AE, Aronoff GR. Personalized Anemia Management and Precision Medicine in ESA and Iron Pharmacology in End-Stage Kidney Disease. Semin Nephrol. 2018 Jul;38(4):410-417.

BOOK CHAPTERS:

Aronoff GR, Abel SR: Principles of administering drugs to patients with renal failure. In: Brenner BM, Stein J, (eds), Contemporary Issues in Nephrology, New York, Churchill-Livingston, 1987.

Bennett WM, Aronoff GR, Golper TA, Morrison G, Singer I, Brater DL: Drug prescribing in renal failure. Dosing guidelines for adults. American College of Physicians, Philadelphia, 1987.

Aronoff GR, Abel SR: I. Antibiotics. The aminoglycosides. In: Aronoff GR (ed), Practical guidelines for drug therapy in dialysis. Seminars in Dialysis 1988;1:62-65.

Abel SR, Aronoff GR: II. Antibiotics. The beta-lactams. In: Aronoff GR (ed), Practical guidelines for drug therapy in dialysis. Seminars in Dialysis 1988;1:112-115.

Matzke GR, Schwenk MH, Keane WF: Antifungal, antitubercular, and antiviral agents. In: Aronoff GR (ed), Practical guidelines for drug therapy in dialysis. Seminars in Dialysis 1988;1:170-173.

Sokolek CM, Aronoff GR: Renal Rehabilitation. In: Malone T (ed), Physical and Occupational Therapy: Drug Implications for Practice. Philadelphia, J. B. Lippincott, 1989.

Matzke GR, Schwenk MH, Keane WF: Antibiotics: Antianaerobic agents, quinolones, and tetracyclines. In: Aronoff GR (ed), Practical guidelines for drug therapy in dialysis. Seminars in Dialysis 1988;1:220-223.

Duff DR: Recombinant Human Erythropoietin. In: Aronoff GR (ed), Practical guidelines for drug therapy in dialysis. Seminars in Dialysis 1989;2:238-240.

Aronoff GR and Abel SR: Practical guidelines for drug dosing in patients with renal impairment. In: Schrier RW (ed), Manual of Nephrology: Diagnosis and Therapy, Third Edition. Boston, Little, Brown, and Company, 1990.

Bennett WM, Aronoff GR, Golper TA, Morrison G, Singer I, Brater DL: Drug prescribing in renal failure. Dosing guidelines for adults. American College of Physicians, Philadelphia, 1991.

Aronoff GR, Erbeck KR: Drug Prescribing For Dialysis Patients. In: Henrich WL (ed). Principles and Practice of Dialysis. Baltimore. Williams & Wilkins, 1994; pp. 89-97.

Erbeck KM, Aronoff GR: The use of anesthetic drugs in patients with impaired renal function. In: Kaufman & Taberner, (eds). Pharmacology in the Practice of Anesthesia. Kent, England. Edward Arnold. pp 492-499, 1996.

Aronoff GR, Abel SR: Practical Guidelines For Drug Dosing in Renal Impairment. In: Schrier, RW (ed). Manual of Nephrology, Fourth Edition. Boston. Little, Brown, & Co.

Ouseph R, Brier M, Aronoff G: Use of drugs in renal failure. In: Kassirer and Greene (eds), Current Therapy in Adult Medicine. 1997

Ouseph R, Brier M, Aronoff G: Use of drugs in renal failure. In: Glasscock (ed), Current Therapy of Nephrology and Hypertension. 1997

Aronoff GR, Erbeck KR: Drug Prescribing For Dialysis Patients. In: Henrich WL (ed). Principles and Practice of Dialysis. Baltimore. Williams & Wilkins, pp. 89-97, 1998.

Ward RA and Aronoff GR: Anticoagulation strategies during hemodialysis procedures. In Henrich WL, (ed). Principles and Practice of Dialysis, (2nd Edition), Williams and Wilkins, Baltimore, MD, 1998; pp. 70-78.

Aronoff GR, Berns J, Brier ME, Golper TA, Morrison G, Singer I, Swan S, Bennett WM: Drug Prescribing in Renal Failure. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, (4th Edition), American College of Physicians, Philadelphia, Pennsylvania, 1999, pp. 1-176.

Aronoff GR: Drug Dosing in Renal Failure. In: Malluche HH, Sawaya BP, Hakim RM, Sayegh MH, Ismail N (eds). Clinical Nephrology, Dialysis and Transplantation. (5th Edition), Dustri-Verlag Dr. Karl Feistle, Landshut, Germany, 1999, pp. 3-30, .

Aronoff G, Brier M, Erbeck K, Ouseph R: Drug Dosing in Dialysis Patients. In: Owen WF, Periera BJG and Sayegh MH, (eds). Dialysis and Transplantation: A Companion to Brenner and Rector's The Kidney, W.B. Saunders Company, Philadelphia, Pennsylvania, 1999, pp. 358-372.

Aronoff GR: Practical Guidelines for Drug Dosing in Patients with Renal Impairment. In Schrier RW (ed.). Manual of Nephrology. (5th Edition), Lippincott Williams and Wilkins, Philadelphia, Pennsylvania, 2000, pp. 182-202.

Aronoff GR, Brier ME: Prescribing Drugs in Renal Disease. In: Brenner BM (ed). Brenner and Rector's The Kidney. (7th Edition). WB Saunders Company, Philadelphia, Pennsylvania, 2003, pp. 2849-2870.

Ward RA, Aronoff GR: Anticoagulation Strategies During Hemodialysis Procedures. In: Henrich WL (ed). Principles and Practice of Dialysis (3rd Edition). Lippincott Williams and Wilkins, Philadelphia, Pennsylvania, 2004, pp. 73-81.

Aronoff GR: Drug Dosing in Chronic Kidney Disease. In: Pereira BJK, Sayegh MH and Blake PG (eds). Chronic Kidney Disease, Dialysis & Transplantation: Companion to Brenner & Rector's The Kidney. (2nd Edition) WB Saunders Company, Philadelphia, Pennsylvania, 2004, pp. 853-869.

Aronoff GR, Brier ME: Prescribing Drugs for Dialysis Patients. In: Heinrich WL (ed). Principles and Practice of Dialysis (3rd Edition). Lippincott Williams and Wilkins, Philadelphia, Pennsylvania, 2004, pp. 147-161.

Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, Smoyer WE: Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, (5th Edition), American College of Physicians, Philadelphia, Pennsylvania, 2007.

Aronoff GR, Brier ME: Practical Guidelines for Drug Dosing in Patients with Impaired Kidney Function. In Schrier RW (ed.). Manual of Nephrology. (7th Edition), Lippincott Williams and Wilkins, Philadelphia, Pennsylvania, 2009, pp. 270-296.